Zyvox

Type: Product
Name: Zyvox
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Mifeprex kit is called as RU486 or pharmaceutical fetus removal

)Pressbox (Press Release) -25 August 2014, Dallas, Texas, USA, (http://daynighthealthcare.co/) : Therapeutic Abortion (brand name Mifeprex) is a type of right on time fetus removal brought about by the mixture of two pharmaceuticals, mifepristone and ... [Published Pressbox.co.uk - Aug 27 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 2 reports

TB Drugs - Poor Countries Hanging By the Thread

Julius Kiiza, 26, was like many youths his age a few years back. He loved to hang out and live a good life. Never in his wildest dreams did he think he was developing a virulent form of tuberculosis - the multi- drug resistant TB (MDR-TB). I met him at ... [Published Individual.com - Aug 27 2014]
Entities: Patent, Uganda, Drugs, HIV/AIDS
First reported Aug 22 2014 - Updated Aug 23 2014 - 1 reports

Cubist nears another big antibiotic approval as M&A rumors simmer

Lexington, MA's Cubist Pharmaceuticals ($CBST) is inching toward its second drug approval of the year, hoping to win European and U.S. clearance for a new anti-infective as analysts wonder whether the company is in line for a Big Pharma takeout.The European ... [Published FierceBiotech - Aug 22 2014]
First reported Aug 18 2014 - Updated Aug 19 2014 - 1 reports

Stock Update (NYSE:PFE): Pfizer Announces Submission of Palbociclib New Drug Application to the FDA

[Business Wire] – Pfizer Inc. today announced it has completed the submission of a New Drug Application to the United States Food and Drug Administration for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for ... [Published Jutia Group - Aug 18 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Should deal-needy Pfizer target antibiotics specialist Cubist?

Forget tax-advantaged Irish drugmakers. It may be a good time to take over an antibiotics maker on the cheap--and analysts have just the antibiotics maker in mind.The mounting threat from drug-resistant germs has triggered a need for newer, stronger antibiotics, ... [Published FiercePharma - Aug 18 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Stock Update (NYSE:PFE): Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica® Studies Conducted in China

[at noodls] – NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today top-line results from two placebo-controlled studies conducted in China with Lyrica® (pregabalin) in patients with postherpetic neuralgia …Read more on this.Pfizer Inc. (PFE) ... [Published Jutia Group - Aug 13 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Dr Le Fanu's online health clinic, Friday 8th August 2014

Concerned about aches and pains? Worried about a medical condition? You can email your questions confidentially to Dr Le Fanu at drjames@telegraph.co.uk. Answers will be published in the health section of the Telegraph website every Friday. Today - restless ... [Published Telegraph - Aug 08 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Pfizer net earnings dips by 79% in Q2 to $2,912 million

Pfizer Inc, a second largest pharmaceutical company in the world after Novartis, has suffered heavy setback during the second quarter ended June 2014 on account of one time income received from sell of animal health business, Zoetis Inc.,  for a consideration ... [Published PharmaBiz - Jul 30 2014]
First reported Jul 29 2014 - Updated Jul 30 2014 - 1 reports

Earnings at Pfizer tank but still just beat expectations

Taking the brunt of generic competition to former blockbuster drugs, US pharma giant Pfizer (NYSE: PFE) posted a massive 79.4% drop in second-quarter 2014 earnings.Earnings plunged to $2.91 billion, or $0.45 per share, minus 77.3%, compared with $14.1 ... [Published Pharma Letter - Jul 29 2014]
Entities: Pfizer Inc, Prevnar, Enbrel
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Pfizer Inc (NYSE:PFE) | Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ALFA (BeneFIX®) Once-Weekly Prophylaxis For Hemophilia B

[at noodls] – Pfizer Inc. (NYSE:PFE) today announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX ® Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment …Read more on this.Pfizer Inc. (PFE) ... [Published Jutia Group - Jul 29 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Pfizer Inc. (PFE) Q2 Earnings Preview: A Penny Here a Penny There

Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 29, 2014. The purpose of the call is to provide an update on Pfizer's results, ... [Published I Stock Analyst - Jul 28 2014]
First reported Jul 26 2014 - Updated Jul 26 2014 - 1 reports

Hypoglycemia and Linezolid

A small number of incidents have shown that linezolid, an antibiotic, may have an association with hypoglycemia....A small number of incidents have shown that linezolid, an antibiotic, may have an association with hypoglycemia....Linezolid (Zyvox) belongs ... [Published Diabetes in Control - Jul 26 2014]

Quotes

"Uganda needs to develop collaborative research so that our scientists can catch up with others in the developed world and partnerships such as the Global Alliance for TB drug development should be more actively supported to allow for the development of drugs that are free of patent restriction" Tabaro urges
Antibiotics "have life-saving power and yet people are only paying hundreds or a couple thousand dollars for them," he told Bloomberg. "You should be able to increase prices consistently for a long period of time."
...While not a controlled clinical study like those that are performed in the present day, the scientists conducting the study noted that "bacteriophages hold enormous possibilities as a new weapon for fighting infectious diseases."
"Cubicin's once-daily dosing, its activity against MRSA, and its favorable safety and tolerability profile make this agent an attractive option for use as OPAT" said Decision Resources Analyst Hannah Cummings

More Content

All (33) | News (29) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Mifeprex kit is called as RU486 or pharmaceutic... [Published Pressbox.co.uk - Aug 27 2014]
TB Drugs - Poor Countries Hanging By the Thread [Published Individual.com - Aug 27 2014]
Uganda: TB Drugs - Poor Countries Hanging By th... [Published AllAfrica.com - Aug 27 2014]
Oragenics: Interview With CEO Bonfiglio [Published Seeking Alpha - Aug 24 2014]
Cubist nears another big antibiotic approval as... [Published FierceBiotech - Aug 22 2014]
Stock Update (NYSE:PFE): Pfizer Announces Submi... [Published Jutia Group - Aug 18 2014]
Should deal-needy Pfizer target antibiotics spe... [Published FiercePharma - Aug 18 2014]
Cubist Battling Superbugs Offers Remedy for J&J... [Published Bloomberg - Aug 18 2014]
butorphanol (Stadol) [Published MedicineNet.com - Aug 13 2014]
Stock Update (NYSE:PFE): Pfizer Reports Top-lin... [Published Jutia Group - Aug 13 2014]
Dr Le Fanu's online health clinic, Friday 8th A... [Published Telegraph - Aug 08 2014]
Company Update (NYSE:PFE): Pfizer to pay $35 ml... [Published Jutia Group - Aug 06 2014]
AmpliPhi Biosciences: Developer Of Antibacteria... [Published Seeking Alpha - Aug 05 2014]
Hospital Acquired Bacterial Infections Market -... [Published MyNewsDesk - Aug 05 2014]
Market Update: Pfizer Inc (NYSE:PFE) – Pfizer E... [Published Jutia Group - Aug 04 2014]
DOES ANYONE CARE? [Published The Week - Aug 04 2014]
oxycodone, Oxycontin, Roxicodone, Oxect [Published MedicineNet.com - Aug 01 2014]
Tedizolid phosphate: Oral and I.V. antibiotic f... [Published Pharmacist.com - Aug 01 2014]
Pfizer net earnings dips by 79% in Q2 to $2,912... [Published PharmaBiz - Jul 30 2014]
Pfizer Inc (NYSE:PFE) | Pfizer Announces Positi... [Published Jutia Group - Jul 29 2014]
Earnings at Pfizer tank but still just beat exp... [Published Pharma Letter - Jul 29 2014]
Tedizolid: A New Oxazolidinone -- Shorter and G... [Published WebMD - Jul 28 2014]
Pfizer Inc. (PFE) Q2 Earnings Preview: A Penny ... [Published I Stock Analyst - Jul 28 2014]
Hypoglycemia and Linezolid [Published Diabetes in Control - Jul 26 2014]
Pfizer's Incoming Patent Cliff [Published Motley Fool - Jul 24 2014]
Tedizolid: A New Oxazolidinone -- Shorter and G... [Published Diabetes Care - Jul 24 2014]
7 Companies That Attempted to Silence Whistlebl... [Published Wall St. Cheat Sheet - Jun 19 2014]
Will Pfizer Try Again for AstraZeneca? [Published Wall St. Cheat Sheet - May 21 2014]
Despite Generic Vancomycin's Continued Dominanc... [Published PR Newswire: Health - May 06 2014]
Pfizer's Double Disappointment a Good Buying Op... [Published The Street Latest - May 05 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
7 Companies That Attempted to Silence Whistlebl... [Published Wall St. Cheat Sheet - Jun 19 2014]
Source: http://www.flickr.com/photos/stevendepolo/ Names like Daniel Ellsworth, Edward Snowden, and Julian Assange have become forever etched in the American lexicon. These individuals, along with troves of others, have single-handedly been able ...
Will Pfizer Try Again for AstraZeneca? [Published Wall St. Cheat Sheet - May 21 2014]
Source: Getty Images There is a misconception among investors that Pfizer ( NYSE:PFE ) was only trying to acquire AstraZeneca ( NYSE:AZN ) to gain access to a country with a corporate tax rate of 21 percent, far lower than the 35 percent rate ...
Despite Generic Vancomycin's Continued Dominanc... [Published PR Newswire: Health - May 06 2014]
BURLINGTON, Mass., May 6, 2014 /PRNewswire/ -- Decision Resources Group finds that overall, infectious disease (ID) specialists and non-ID physicians (critical care and internal medicine specialists) prefer the branded agents Cubist's Cubicin (daptomycin) ...
1

Press Releases

sort by: Date | Relevance
Current MRSA Antibiotics Will Face Competition ... [Published PR Newswire - Nov 19 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.